Odyssey Therapeutics reported a third-quarter 2026 net loss of $53.1 million, compared to a $35.5 million loss in the prior-year period. Research and development expenses rose to $42.1 million from $26.3 million due to higher external costs for clinical programs, while general and administrative expenses increased to $11.2 million. The company held $387 million in cash and marketable securities as of September 30, 2026, which is expected to fund operations into the second half of 2028. Additionally, Odyssey appointed Anthony Opipari as chief medical officer to ensure continuity of clinical leadership. Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases.
